165 related articles for article (PubMed ID: 19930613)
1. Cellular responses to modified Plasmodium falciparum MSP119 antigens in individuals previously exposed to natural malaria infection.
Okafor CM; Anumudu CI; Omosun YO; Uthaipibull C; Ayede I; Awobode HO; Odaibo AB; Langhorne J; Holder AA; Nwuba RI; Troye-Blomberg M
Malar J; 2009 Nov; 8():263. PubMed ID: 19930613
[TBL] [Abstract][Full Text] [Related]
2. An engineered Plasmodium falciparum C-terminal 19-kilodalton merozoite surface protein 1 vaccine candidate induces high levels of interferon-gamma production associated with cellular immune responses to specific peptide sequences in Gambian adults naturally exposed to malaria.
Bisseye C; Yindom LM; Simporé J; Morgan WD; Holder AA; Ismaili J
Clin Exp Immunol; 2011 Dec; 166(3):366-73. PubMed ID: 22059995
[TBL] [Abstract][Full Text] [Related]
3. Malaria parasite-inhibitory antibody epitopes on Plasmodium falciparum merozoite surface protein-1(19) mapped by TROSY NMR.
Morgan WD; Lock MJ; Frenkiel TA; Grainger M; Holder AA
Mol Biochem Parasitol; 2004 Nov; 138(1):29-36. PubMed ID: 15500913
[TBL] [Abstract][Full Text] [Related]
4. Human leukocyte antigen class II alleles influence levels of antibodies to the Plasmodium falciparum asexual-stage apical membrane antigen 1 but not to merozoite surface antigen 2 and merozoite surface protein 1.
Johnson AH; Leke RG; Mendell NR; Shon D; Suh YJ; Bomba-Nkolo D; Tchinda V; Kouontchou S; Thuita LW; van der Wel AM; Thomas A; Stowers A; Saul A; Zhou A; Taylor DW; Quakyi IA
Infect Immun; 2004 May; 72(5):2762-71. PubMed ID: 15102786
[TBL] [Abstract][Full Text] [Related]
5. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
[TBL] [Abstract][Full Text] [Related]
6. Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.
Elias SC; Collins KA; Halstead FD; Choudhary P; Bliss CM; Ewer KJ; Sheehy SH; Duncan CJ; Biswas S; Hill AV; Draper SJ
J Immunol; 2013 Feb; 190(3):1135-47. PubMed ID: 23293353
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of the profiles of IgG subclass-specific responses to Plasmodium falciparum apical membrane antigen-1 and merozoite surface protein-1 in naturally exposed individuals living in malaria hypoendemic settings, Iran.
Rouhani M; Zakeri S; Mehrizi AA; Djadid ND
Malar J; 2015 Feb; 14():58. PubMed ID: 25652589
[TBL] [Abstract][Full Text] [Related]
8. Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.
Otsyula N; Angov E; Bergmann-Leitner E; Koech M; Khan F; Bennett J; Otieno L; Cummings J; Andagalu B; Tosh D; Waitumbi J; Richie N; Shi M; Miller L; Otieno W; Otieno GA; Ware L; House B; Godeaux O; Dubois MC; Ogutu B; Ballou WR; Soisson L; Diggs C; Cohen J; Polhemus M; Heppner DG; Ockenhouse CF; Spring MD
Malar J; 2013 Jan; 12():29. PubMed ID: 23342996
[TBL] [Abstract][Full Text] [Related]
9. The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies.
Nwuba RI; Sodeinde O; Anumudu CI; Omosun YO; Odaibo AB; Holder AA; Nwagwu M
Infect Immun; 2002 Sep; 70(9):5328-31. PubMed ID: 12183594
[TBL] [Abstract][Full Text] [Related]
10. Dominance of conserved B-cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood-stage infections of naive Aotus monkeys.
Hui GS; Nikaido C; Hashiro C; Kaslow DC; Collins WE
Infect Immun; 1996 May; 64(5):1502-9. PubMed ID: 8613353
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
12. The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes.
de Silva HD; Saleh S; Kovacevic S; Wang L; Black CG; Plebanski M; Coppel RL
Malar J; 2011 Sep; 10():266. PubMed ID: 21920045
[TBL] [Abstract][Full Text] [Related]
13. Plasmodium falciparum malaria in the Peruvian Amazon, a region of low transmission, is associated with immunologic memory.
Clark EH; Silva CJ; Weiss GE; Li S; Padilla C; Crompton PD; Hernandez JN; Branch OH
Infect Immun; 2012 Apr; 80(4):1583-92. PubMed ID: 22252876
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness.
Stanisic DI; Richards JS; McCallum FJ; Michon P; King CL; Schoepflin S; Gilson PR; Murphy VJ; Anders RF; Mueller I; Beeson JG
Infect Immun; 2009 Mar; 77(3):1165-74. PubMed ID: 19139189
[TBL] [Abstract][Full Text] [Related]
15. Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.
Elias SC; Choudhary P; de Cassan SC; Biswas S; Collins KA; Halstead FD; Bliss CM; Ewer KJ; Hodgson SH; Duncan CJ; Hill AV; Draper SJ
Immunology; 2014 Apr; 141(4):628-44. PubMed ID: 24303947
[TBL] [Abstract][Full Text] [Related]
16. Antibody and cellular immune responses to Plasmodium falciparum histidine-rich protein II in malaria-exposed individuals in Orissa, India.
Das P; Grewal JS; Chauhan VS
Trans R Soc Trop Med Hyg; 2010 May; 104(5):371-3. PubMed ID: 20116080
[TBL] [Abstract][Full Text] [Related]
17. Linkage of exogenous T-cell epitopes to the 19-kilodalton region of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) can enhance protective immunity against malaria and modulate the immunoglobulin subclass response to MSP1(19).
Ahlborg N; Ling IT; Holder AA; Riley EM
Infect Immun; 2000 Apr; 68(4):2102-9. PubMed ID: 10722607
[TBL] [Abstract][Full Text] [Related]
18. Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort.
Adamou R; Dechavanne C; Sadissou I; d'Almeida T; Bouraima A; Sonon P; Amoussa R; Cottrell G; Le Port A; Theisen M; Remarque EJ; Longacre S; Moutairou K; Massougbodji A; Luty AJF; Nuel G; Migot-Nabias F; Sanni A; Garcia A; Milet J; Courtin D
Malar J; 2019 Jun; 18(1):194. PubMed ID: 31185998
[TBL] [Abstract][Full Text] [Related]
19. Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies.
Guevara Patiño JA; Holder AA; McBride JS; Blackman MJ
J Exp Med; 1997 Nov; 186(10):1689-99. PubMed ID: 9362529
[TBL] [Abstract][Full Text] [Related]
20. Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum.
Egan AF; Chappel JA; Burghaus PA; Morris JS; McBride JS; Holder AA; Kaslow DC; Riley EM
Infect Immun; 1995 Feb; 63(2):456-66. PubMed ID: 7822010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
